VOR Vor Biopharma Inc.

NEUTRAL Impact: 3/10 Institutional Cluster
Horizon weeks Processed 2d 5h ago
Institutional cluster: 5 buyers, 0 sellers (bullish)

Executive Summary

Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) collectively more than doubled their VOR positions in Q4 2025, adding $31.8M in new holdings to reach $50.8M total. This is an index-driven rebalancing move, likely reflecting VOR's continued inclusion in growth/small-cap passive mandates, not an active conviction thesis. The net 11% win rate on prior VOR reports at T+20 and negative historical calibration for this segment caution against over-weighting the signal.

Key Financial Metrics

Direction
accumulating
Buy Value
$50.8M
Net Flow
$31.8M

Institutional Positions

Net institutional flow: $31.8M

▲ Buyers (5)

InstitutionActionChangePosition ValueValue Δ
Vanguard DOUBLED +632.2% $10.1M $5.0M
BlackRock DOUBLED +1248.5% $6.1M $4.4M
State Street DOUBLED +905.7% $1.2M $750.0K
Fidelity DOUBLED +968.1% $33.0M $21.5M
Morgan Stanley DOUBLED +538.8% $372.0K $155.0K

Actionable Insight

The buying is entirely mega-passive, reflecting index rebalancing rather than active conviction. Monitor for active fund interest (e.g., healthcare-specialist hedge funds or biotech-focused funds) as a stronger signal. The historical T+20 drift for VOR reports is negative on balance, suggesting fading this passive accumulation is the higher-probability trade near term.

Key Facts

  • 5 institutions accumulated $31.8M net in VOR during Q4 2025, bringing aggregate holdings to $50.8M
  • Every buyer was a mega-passive fund: Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley
  • All five funds DOUBLED or more their positions (range: +539% to +1249% share increases)
  • Zero institutional sellers detected in this cluster
  • Prior VOR reports have a T+20 win rate of only 11%, with historical net alpha of -2.1% T+20 in this filing segment

Financial Impact

5 institutions accumulated $31.8M in new VOR holdings, increasing total disclosed institutional position value from $19.0M to $50.8M

institutional ownershipfloat concentration

Risk Factors

  • No active or catalyst-driven buyers — all accumulation is passive/index rebalancing, which carries weaker predictive signal
  • 13F data is stale (45-day lag); positions may have already been unwound or adjusted
  • Historical calibration shows negative expected alpha at T+20 for this filing segment

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
85% bullish (13 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-VOR-2025-Q4
7 reports for VOR
Performance horizon
Filters
Rows
Reports for VOR — sortable, filterable
Type Now
Jun 11, 2026
2d ago
Institutional Cluster
NEUTRAL ★ 3/10
$13.00 awaiting T+20awaiting T+20
Jun 8, 2026
5d ago
Press Release
BULLISH ★ 7/10
$13.10 awaiting T+20awaiting T+20
May 7, 2026
5w ago
EFFECT
NEUTRAL ★ 3/10
$16.08 $13.44▼ −16.42%▼ −19.55%
Apr 27, 2026
6w ago
S-3
NEUTRAL ★ 3/10
$14.38 $14.10▼ −1.95%▼ −7.42%
Apr 27, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$14.38 $14.10▼ −1.95%▼ −7.42%
Mar 27, 2026
11w ago
Press Release
NEUTRAL ★ 5/10
$14.48 $14.12▼ −2.49%▼ −15.23%
Mar 23, 2026
11w ago
Press Release
NEUTRAL ★ 3/10
$12.15 $15.32▲ +26.09%▲ +17.19%
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (45h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access